Login to Your Account

Amgen Reports Positive Vectibix, Denosumab Data at ECCO-ESMO

By Donna Young

Wednesday, September 23, 2009
New Phase III data presented at the 2009 ECCO-ESMO European Multidisciplinary Congress in Berlin showed that Amgen Inc.'s Vectibix (panitumumab) plus chemotherapy used as a second-line treatment significantly improved progression-free survival (PFS) in patients with KRAS wild-type metastatic colorectal cancer compared with chemotherapy alone, 5.9 months vs. 3.9 months. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription